Thalassemia and Sickle Cell Anaemia are common genetic disorders, with options for treatment and prevention available.

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination ...